Following a bruising U.S. Supreme Court fight last year that invalidated two of its human gene patents, Myriad Genetics Inc. is using related patents to sue a new set of competitors—but faces an aggressive counterattack.
GeneDx Inc., one of Myriad’s litigation opponents in In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation, which is pending in Utah federal court, this week filed 11 petitions for so-called inter partes review of 11 patents owned, co-owned or licensed by Myriad.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
